Tag: psilocin

Cybin posts second-quarter loss widens as clinical trials advance

The company still ended the quarter on a pile of cash to support its R&D efforts. Toronto-based Cybin Inc. (NYSE: CYBN) reported financials for its fiscal second quarter 2025 ending Sept. 30, with higher R&D costs from its clinical programs. The company also announced it has initiated a phase 3 program evaluating its psilocin-based CYB003 […]

Tryptamine Therapeutics raises A$6M to advance psychedelic pipeline

Australian biotech firm Tryptamine Therapeutics Limited (ASX: TYP) secured A$6 million in new funding through a strategic placement. The placement, priced at A$0.02 per share, was backed by cornerstone investors that included Merchant Biotech Fund and biotech investor Daniel Tillett, who will join the company’s board as a non-executive director, the company said in an […]